companies

Medical Microinstruments

Founded 2015
Employees 100+
Primary contact
Via Egidio Giannessi 52-54-56
56121 Pisa
Tuscany
Italy
+39 050 879 692
Links
https://www.mmimicro.com/
Sections
Technologies
Medical Microinstruments (MMI) aims to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes in microsurgery. The company's Symani Surgical System combines proprietary innovations including the world's smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies. Together, these powerful capabilities allow more surgeons to successfully perform microsurgery while expanding the field of super microsurgery and reducing costs for patients, hospitals, and for society at large.
Select partners: University Hospital Salzburg, Careggi University Hospital in Florence, University Hospital Salzburg, University Hospital Zurich, VirtaMed.
Founded 2015
Employees 100+
Primary contact
Via Egidio Giannessi 52-54-56
56121 Pisa
Tuscany
Italy
+39 050 879 692
Links
https://www.mmimicro.com/
Sections
Technologies

Funding 💰

Total $99.8M
Last round 🔗 $75M
Series B
July 20, 2022.
Select investors Deerfield Management, Andera Partners, Panakes Partners, Fountain Healthcare Partners, RA Capital Management, BioStar Capital, European Investment Bank

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • It works: In July 2021, MMI's Symani Surgical System was successfully used at Careggi University Hospital Florence by Prof. Marco Innocenti and his team in a complex, post-traumatic limb reconstruction that saved a patient's arm from amputation. The case was the first enrolled patient in MMI's post-market study. 🔗
  • Expansion plans: On the heels of its Series B round of financing, the company announced plans for expansion to more countries in Europe, the United States, and Asia-Pacific. To that end, in January 2021, MMI appointed healthcare industry veteran Mark Toland as Chief Executive Officer.
  • Growing market: The global microsurgery market size is expected to reach $3.38 Billion in 2030 and register a revenue CAGR of 6.9% over the forecast period, according to the report by Reports and Data. Some of the major factors driving market revenue growth include the major prevalence of breast cancer and skin cancer, increasing global geriatric population, and higher preference for minimally invasive surgical procedures. 🔗
  • Certified: The Symani Surgical System received CE Mark in 2019 and is also ISO 13485 certified. MMI plans to secure an Investigational Device Exemption (IDE) from the U.S. FDA to conduct a pivotal study.

Video ▶️

Quotes 💬

“
The MMI technology is one of the most significant transformational advancements in surgical robotics that we have seen. Having the world's smallest wristed instruments opens up the field of 'micro' robotics to a completely new level of treatment spanning microsurgery for cancer, trauma, orthopedic, pediatric, and one day, neurosurgery patients. Symani will be the future of how microsurgery is performed worldwide.
— Dr. Andrew ElBardissi, partner at Deerfield Management 🔗
“
Robotic microsurgery has enormous potential to both improve the standard of care for patients and help surgeons manage procedures that require delicate precision. I look forward to supporting MMI and its world-class team as it begins this exciting chapter.
— Tess Cameron, principal for RA Capital Management 🔗
Last update: January 13, 2023